Sale of Assets from the Bankruptcy Estate of Stayble Therapeutics AB – Expression of Interest Regarding Patents and Clinical Data Related to STA363
Stayble Therapeutics AB, reg. no. 559024-8372 (the ”Company”), was declared bankrupt by the Gothenburg District Court on June 2, 2026. Attorney-at-law Patric Lundin has been appointed as bankruptcy trustee. The undersigned is assisting the bankruptcy trustee in the administration of the bankruptcy estate.
The purpose of this letter is to explore your potential interest in acquiring the Company’s intellectual property assets, including patents, patent applications, clinical study data and regulatory documentation related to the drug candidate STA363. In addition, certain former key employees of the Company may be available and willing to continue their engagement under a new owner, which could facilitate a seamless transition and continued development of STA363.
STA363 is a locally acting, single-injection treatment designed to address pain caused by lumbar disc herniation (LDH). The treatment is disease-modifying and aims to reduce disc volume, relieve nerve pressure and target the biological root cause of the patient’s pain. STA363 constitutes a non-surgical, second-line alternative for patients who have not responded to physiotherapy or analgesics. The drug candidate has patent protection through 2041, with potential extensions in the US and other jurisdictions until 2046.
The Company has completed a Phase 1b study in LDH (approximately 25 patients), demonstrating reduced disc volume and a favorable safety profile. In total, approximately 100 patients have been treated with STA363, with a documented strong safety and tolerability profile as well as clear efficacy signals on relevant biomarkers. At the time of the bankruptcy, the Company had achieved Phase 2b readiness, with the study protocol under finalization, API production secured and CRO agreements in place.
Further information regarding the Company and STA363 is available on the Company’s website at https://staybletherapeutics.com/. Please also refer to the enclosed company presentation for additional details.
Following an expression of interest, the bankruptcy estate intends to provide interested parties with a bid package containing further details regarding the assets and the terms of the sale process. Access to such information will be conditional upon the prior execution of a non-disclosure agreement (NDA). In addition, interested parties will be given the opportunity to direct questions to the Company’s former CEO to facilitate their evaluation of the assets.
Should you wish to explore this opportunity further, or if you have any questions, please do not hesitate to contact the undersigned at alexandra.thornroos@wahlinlaw.se or +46 70 499 24 76. We kindly ask that you respond no later than June 19, 2026.
Download Company Presentation (PDF):
Stayble Therapeutics AB – Company presentation 2026
Advokat / Partner
Patric has more than 20 years of experience in advanced legal work within insolvency law and debt recovery. He primarily serves as an advisor to companies, their representatives, and owners in matters related to insolvency law and associated issues. Additionally, he deals with general business law, commercial agreements, issues related to the Swedish Companies Act, etc. Patric is also active as a bankruptcy administrator.
Advokat
Alexandra specialises in insolvency law issues related to bankruptcy and liquidation, as well as handling business transfers and other commercial transactions. She also has experience in corporate law, as well as real estate and tenancy law.
Stayble Therapeutics is dedicated to developing an effective treatment option for lumbar disc herniation (LDH) using the company's drug candidate, STA363. This minimally invasive treatment offers an efficient and simple solution for the millions of individuals suffering from pain, where pain medication or physical therapy have proven ineffective.
Read more
Stayble Therapeutics AB ("Stayble" eller "Bolaget") offentliggör härmed halvårsrapport för 2025. Rapporten finns tillgänglig som bifogat dokument samt på Bolagets hemsida, www.staybletherapeutics.com/sv/investerare/finansiella-rapporter/. Nedan följer en...
Stayble Therapeutics AB, org.nr 559024-8372 (”Bolaget”), har hållit årsstämma idag den 5 juni 2025 på Bolagets kontor i Göteborg. Vid stämman fattades beslut om huvudsakligen...
STA363 towards disc herniation place Stayble in a the forefront of injection-based, minimally invasive treatments for leg pain. As Stayble has developed successfully, the Company is competing to become the market leader in second-line therapies for pain caused by disc hernia.
About Stayble
We are currently conducting a clinical phase 1b study in disc herniation. Read more about the study below.
LDH CANDIDATEStayble is listed on Nasdaq First North under the ticker STABL. You will find all relevant information on the Stayble share in our Investors section.
Investors
The majority of patients suffering from unresolved disc hernia are not helped by conservative treatment with analgesics and physiotherapy. With no long term treatment options than surgery most of these patient continues to suffer without improvment.
Stayble’s product STA363 will bridge the gap between conservative and radical therapy to the benefit of millions of patients presently left on their own to cope with sustained and disabling pain.
About Stayble
